Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 2—February 2017

Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel

Ronen Ben-AmiComments to Author , Judith Berman, Ana Novikov, Edna Bash, Yael Shachor-Meyouhas, Shiri Zakin, Yasmin Maor, Jalal Tarabia, Vered Schechner, Amos Adler, and Talya Finn
Author affiliations: Tel Aviv University, Tel Aviv, Israel (R. Ben-Ami, J. Berman, S. Zakin, Y. Maor, V. Schechner, A. Adler); Tel Aviv Sourasky Medical Center, Tel Aviv (R. Ben-Ami, A. Novikov, E. Bash, J. Tarabia, V. Schechner, A. Adler, T. Finn); Ruth Rappaport Children's Hospital, Haifa, Israel (Y. Shachor-Meyouhas); Wolfson Medical Center, Holon, Israel (Y. Maor).

Main Article

Table 1

Characteristics of 9 patients with Candida isolates available for microbiological analyses, Tel Aviv, Israel*

Isolate ID GenBank accession nos.
DNA sequence analysis Patient age, y/sex Hospital/unit Date Comorbidities Culture source Clinical significance Treatment In-hospital outcome
TA001-14 KU896955 KU886685 C. haemulonii 52/M TASMC/vascular clinic 2014 Jun CIDP, steroids, CLU Wound Colonization None Survival
TA001-15 KU896954 KU886684 C. haemulonii 79/M TASMC/vascular clinic 2015 Apr PVD, CKD, DMt2, IHD, pacemaker, CLU Wound Colonization None Survival
TA004-15 KU896956 KU896947 C. haemulonii 69/M TASMC/vascular surgery 2015 Jun PVD, DMt2, IHD, CLU Wound Colonization None Survival
TA003-14 KU896949 KU886679 C. auris 91/F TASMC/medicine 2014 May ANCA vasculitis, M-vent, VAP, steroids, CVC Blood CRBSI Fluconazole Death
TA002-14 KX518348 KU886682 C. auris 79/M TASMC/neurosurgery 2014 Oct MDS, ASDH, M-vent, VAP; CVC Blood CRBSI CVC removed; none Death
TA004-14 KU896950 KU886680 C. auris 74/M TASMC/medicine 2014 Aug CKD, hemodialysis, CVC, pacemaker, IHD, DMt2 Blood CRBSI CVC removed; anidulafungin Survival
TA005-14 KU896951 KU886681 C. auris 57/F TASMC/medicine 2014 May PBC Blood Primary candidemia Fluconazole; anidulafungin Survival
TA003-15 KU896953 KU886683 C. auris 42/M WMC/medicine 2015 Apr IVDU, HIV, HBV, HCV, MRSA sepsis Blood Primary candidemia Fluconazole; voriconazole Survival
TA002-15 KU896948 KU886678 C. auris 79/M TASMC/medicine 2015 Apr CKD, DMt2, IHD, PICC Urine Asymptomatic candiduria None Survival

*CIDP, chronic inflammatory demyelinating polyneuropathy; CKD, chronic kidney disease; CLU, chronic leg ulcers; CRBSI, catheter-related bloodstream infection; CVC, central venous catheter; DMt2, diabetes mellitus type 2; HBV, hepatitis B virus infection; HCV, hepatitis C virus infection; IHD, ischemic heart disease; ITS, internal transcribed spacer; IVDU, intravenous drug user; LSU, large subunit; MRSA, multidrug-resistant Staphylococcus aureus; M-vent, mechanical ventilation; PBC, primary biliary cirrhosis; PICC, peripherally inserted central catheter; PVD, peripheral vascular disease; TASMC, Tel Aviv Sourasky Medical Center; VAP, ventilator-associated pneumonia; WMC, Wolfson Medical Center.

Main Article

Page created: January 12, 2017
Page updated: January 12, 2017
Page reviewed: January 12, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.